BUDGET IMPACT ANALYSIS (BIA) POLYSACCAHARIDE CAPSULAR VI TYPHOID IN INDONESIA
Typhoid fever that is caused by Salmonella typhi has a substantial economic impact in developing countries, such as Indonesia. This situation might be caused by a relatively high treatment cost due to typoid fever, including direct cost (medical and non-medical), indirect cost and all costs cover...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/39726 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Typhoid fever that is caused by Salmonella typhi has a substantial economic impact
in developing countries, such as Indonesia. This situation might be caused by a
relatively high treatment cost due to typoid fever, including direct cost (medical
and non-medical), indirect cost and all costs covered by national health insurance
(BPJS Kesehatan). Up to now, a lot of prevention strategies have been conducted.
Yet, the prevalence of typhoid fever in Indonesia remains high. Vaccination is
considered to be the most cost-effective intervention to prevent typhoid fever in
several countries. By applying budget impact analysis (BIA), the purpose of this
study was to identify the impact of polysaccharide capsular Vi typhoid vaccination
on the routine immunization budget. A method of top-down cost analysis was
applied in this study by collecting observed costs from various secondary data to
estimate Incremental cost-effectiveness ratio (ICER) and to analyse the impact of
this new immunization program in a time horizon of 2020 –2024 within two
scenarios: introduction of typhoid vaccine in targeted regions based on disease
burden without nationwide vaccination in 2024 and with nationwide vaccination in
2024. The results showed that vaccination can prevent the number of cases
(outpatient and hospitalization) and the number of death in 2020 –2024 at
consecutive values: 117 and 0; 1,741 and 4; 3,863 and 9; 24,538 and 5; 37,435 and
83 in a scenario without nationwide immunization in 2024 (scenario 1) and 905,821
and 201 in a scenario with nationwide vaccination in 2024 (scenario 2). Compared
with routine immunization budget, total required budget for typhoid vaccination in
2020 –2024 would be 0.05%; 0.93%; 1.74%; 3.74% and 6.63% for scenario 1 and
28.89% for scenario 2 when nationwide vaccination would be implemented in 2024.
From the calculation of ICER, typhoid vaccination in Indonesia can be concluded
as a cost-effective intervention, compared with no vaccination since the required
budget would be 28.89% of total routine immunization budget in Indonesia.
|
|---|